F. Kradolfer
Impact in
- Pharmacology top 5%
- Microbial Natural Products and Biosynthesis
- Antibiotics Pharmacokinetics and Efficacy
- Microbiology top 10%
Papers in
- Pharmacology 12
- Microbial Natural Products and Biosynthesis 8
- Antibiotics Pharmacokinetics and Efficacy 4
-
- Antibiotic Resistance in Bacteria 3
F. Kradolfer
32 papers receiving 484 citations
Peers
Comparison fields: 5 of 93
- Pharmacology 221
- Microbiology 9
- Molecular Medicine 57
- Organic Chemistry 222
- Biotechnology 48
Countries citing papers authored by F. Kradolfer
This map shows the geographic impact of F. Kradolfer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Kradolfer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Kradolfer more than expected).
Fields of papers citing papers by F. Kradolfer
This network shows the impact of papers produced by F. Kradolfer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Kradolfer. The network helps show where F. Kradolfer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside F. Kradolfer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Curative effect of a course of monotherapy with rifampicin, isoniazid or streptomycin subsequent to combination treatment in murine tuberculosis. | 1973 | 2 |
| 2 | [Experimental trials with the new cephalosporin antibiotic celospor (Cephacetril)]. | 1973 | 2 |
| 3 | 1970 | 4 | |
| 4 | Chemotherapeutic activity of new derivatives of rifamycin. | 1966 | 5 |
| 5 | Mode of action of Ciba 32644-Ba in experimental schistosomiasis. | 1966 | 9 |
| 6 | 1964 | 44 | |
| 7 | [Directed control of the intestinal flora with Mexaform and chlortetracycline]. | 1962 | 2 |
| 8 | Ferrimycin A, a new iron-containing antibiotic. | 1962 | 13 |
| 9 | 1962 | 2 | |
| 10 | 1961 | 3 | |
| 11 | [The detoxifying effect of dexamethasone and aldosterone against bacterial lipopoly-saccharides]. | 1960 | 2 |
| 12 | Experimental studies on amebicidal, antibacterial, and antiparasitic phenanthroline compounds. | 1958 | 4 |
| 13 | 1958 | 1 | |
| 14 | 1957 | 1 | |
| 15 | 1957 | 77 | |
| 16 | [Inhibition of viruses and the effect of cells]. | 1957 | 1 |
| 17 | [Viral inhibition in different sera]. | 1957 | 0 |
| 18 | 1957 | 8 | |
| 19 | [Virus inhibition in native milieu]. | 1955 | 1 |
| 20 | [Inhibition of ferments and inhibition of viruses]. | 1954 | 0 |
About F. Kradolfer
F. Kradolfer is a scholar working on Pharmacology, Molecular Medicine, Infectious Diseases, Parasitology and Organic Chemistry, having authored 41 papers that have together received 589 indexed citations. Recurring topics across this work include Microbial Natural Products and Biosynthesis (8 papers), Tuberculosis Research and Epidemiology (6 papers), Synthetic Organic Chemistry Methods (6 papers), Mycobacterium research and diagnosis (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers), Chemical Synthesis and Analysis (3 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Antibiotic Resistance in Bacteria (3 papers). The work is most often cited by research in Pharmacology (221 citations), Microbiology (9 citations), Molecular Medicine (57 citations), Organic Chemistry (222 citations) and Biotechnology (48 citations). F. Kradolfer has collaborated with scholars based in Switzerland, Germany and Austria. Frequent co-authors include L. Neipp, L. Ettlinger, E. Gäumann, O. Zák, Hans Zähner, V. Prelog, R. Corbaz, W. Keller‐Schierlein, P Reusser and R. Meier. Their work appears in journals such as Helvetica Chimica Acta, Cellular and Molecular Life Sciences, Pathobiology, Chemotherapy and The Journal of Antibiotics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.